Symbols

LEGN

Legend Biotech·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 2

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

FDA Approved

RSI Oversold

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LEGN

Legend Biotech Corporation

A company that develops novel cell therapies for oncology and other indications

Industry

Pharmaceutical

Established Date

05/27/2015

Listing Date

06/05/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

2,600

Fiscal Year Ends

12-31

Website

www.legendbiotech.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

2101 Cottontail Lane, Somerset, NJ 08873

Business

Introduction

Legend Biotech Corporation was incorporated in the Cayman Islands as an exempted company on May 27, 2015. The Company is a global clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cell therapies for oncology and other indications, its lead drug candidate LCAR-B38M/JNJ-4528 is a chimeric antigen receptor or CAR, the Company is developing T cell therapies with strategic partners Janssen Biotech, Inc., or Janssen, For the treatment of multiple myeloma or MM.

Earnings Call

Q1/2025

Estimate EPS-0.25

Actual EPS-0.27

Estimate Revenue193.88M

Actual Revenue195.05M

Legend Biotech's Q1 2025: Unpacking Key Contradictions in CARVYKTI Pricing, Market Expansion, and Manufacturing Challenges

May 20,2025 01:47·
Earnings Decrypt

Q2/2025

Estimate EPS-0.2

Actual EPS0.03

Estimate Revenue228.46M

Actual Revenue255.06M

Legend Biotech's Q2 2025: Unpacking Key Contradictions in Community Adoption, Manufacturing, and Market Strategies

Aug 11,2025 01:57·
Earnings Decrypt

Company Financials

EPS

LEGN has released its 2025 Q3 earnings. EPS was reported at -0.05, versus the expected -0.12, beating expectations. The chart below visualizes how LEGN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LEGN has released its 2025 Q3 earnings report, with revenue of 272.33M, reflecting a YoY change of 69.99%, and net profit of -39.69M, showing a YoY change of 68.33%. The Sankey diagram below clearly presents LEGN's revenue sources and cost distribution.